Cargando…

1586. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Biofilms Formed by Staphylococci Isolated from Prosthetic Joint Infection

BACKGROUND: Prosthetic joint infections (PJIs) are serious complications after total joint arthroplasty. Staphylococcus aureus and Staphylococcus epidermidis, which are proficient biofilm-formers, account for ~60% of PJI cases. Therapy often includes rifampin because of its anti-biofilm activity; th...

Descripción completa

Detalles Bibliográficos
Autores principales: Albano, Mariana, Karau, Melissa J, Osmon, Douglas R, Oravec, Caitlin P, Abdel, Matthew P, Patel, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810379/
http://dx.doi.org/10.1093/ofid/ofz360.1450
_version_ 1783462238544199680
author Albano, Mariana
Karau, Melissa J
Osmon, Douglas R
Oravec, Caitlin P
Abdel, Matthew P
Patel, Robin
author_facet Albano, Mariana
Karau, Melissa J
Osmon, Douglas R
Oravec, Caitlin P
Abdel, Matthew P
Patel, Robin
author_sort Albano, Mariana
collection PubMed
description BACKGROUND: Prosthetic joint infections (PJIs) are serious complications after total joint arthroplasty. Staphylococcus aureus and Staphylococcus epidermidis, which are proficient biofilm-formers, account for ~60% of PJI cases. Therapy often includes rifampin because of its anti-biofilm activity; the activity of other rifamycins against staphylococcal biofilms is poorly defined. This study evaluated the in vitro activity of rifampin, rifabutin, rifapentine, and rifaximin against S. aureus and S. epidermidis biofilms formed by isolates from patients with PJI. METHODS: 200 staphylococcal isolates were tested (111 S. aureus and 89 S. epidermidis). All S. aureus isolates, and all except 7 S. epidermidis isolates, were rifampin susceptible. Rifampin, rifabutin, rifapentine, and rifaximin minimum biofilm inhibitory concentrations (MBICs) and minimum biofilm bactericidal concentration (MBBCs) were determined using a pegged lid microtiter plate assay. RESULTS: Rifampin-resistant isolates had MBICs and MBBCs ≥16 µg/mL. Results for the rifampin-susceptible isolates are shown. All 193 rifampin-susceptible isolates had rifampin MBICs ≤1 µg/mL (rifampin-susceptible breakpoint for planktonic susceptibility testing), with 1, 2, and 2 isolates having MBICs > 1 µg/mL for rifabutin, rifapentine and rifaximin, respectively. S. aureus MBBC(50) values were 8, 1, 2 and 4 µg/mL for rifampin, rifabutin, rifapentine and rifaximin, respectively. S. epidermidis MBBC(50) values were 2, 0.06, 0.25, and 0.5 µg/mL for rifampin, rifabutin, rifapentine and rifaximin, respectively, for rifampin-susceptible isolates. CONCLUSION: Rifabutin and rifapentine, and to a lesser extent, rifaximin, show promising in vitro activity against rifampin-susceptible staphylococcal biofilms formed by isolates associated with PJI; studies evaluating in vivo activity are warranted. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810379
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68103792019-10-28 1586. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Biofilms Formed by Staphylococci Isolated from Prosthetic Joint Infection Albano, Mariana Karau, Melissa J Osmon, Douglas R Oravec, Caitlin P Abdel, Matthew P Patel, Robin Open Forum Infect Dis Abstracts BACKGROUND: Prosthetic joint infections (PJIs) are serious complications after total joint arthroplasty. Staphylococcus aureus and Staphylococcus epidermidis, which are proficient biofilm-formers, account for ~60% of PJI cases. Therapy often includes rifampin because of its anti-biofilm activity; the activity of other rifamycins against staphylococcal biofilms is poorly defined. This study evaluated the in vitro activity of rifampin, rifabutin, rifapentine, and rifaximin against S. aureus and S. epidermidis biofilms formed by isolates from patients with PJI. METHODS: 200 staphylococcal isolates were tested (111 S. aureus and 89 S. epidermidis). All S. aureus isolates, and all except 7 S. epidermidis isolates, were rifampin susceptible. Rifampin, rifabutin, rifapentine, and rifaximin minimum biofilm inhibitory concentrations (MBICs) and minimum biofilm bactericidal concentration (MBBCs) were determined using a pegged lid microtiter plate assay. RESULTS: Rifampin-resistant isolates had MBICs and MBBCs ≥16 µg/mL. Results for the rifampin-susceptible isolates are shown. All 193 rifampin-susceptible isolates had rifampin MBICs ≤1 µg/mL (rifampin-susceptible breakpoint for planktonic susceptibility testing), with 1, 2, and 2 isolates having MBICs > 1 µg/mL for rifabutin, rifapentine and rifaximin, respectively. S. aureus MBBC(50) values were 8, 1, 2 and 4 µg/mL for rifampin, rifabutin, rifapentine and rifaximin, respectively. S. epidermidis MBBC(50) values were 2, 0.06, 0.25, and 0.5 µg/mL for rifampin, rifabutin, rifapentine and rifaximin, respectively, for rifampin-susceptible isolates. CONCLUSION: Rifabutin and rifapentine, and to a lesser extent, rifaximin, show promising in vitro activity against rifampin-susceptible staphylococcal biofilms formed by isolates associated with PJI; studies evaluating in vivo activity are warranted. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810379/ http://dx.doi.org/10.1093/ofid/ofz360.1450 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Albano, Mariana
Karau, Melissa J
Osmon, Douglas R
Oravec, Caitlin P
Abdel, Matthew P
Patel, Robin
1586. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Biofilms Formed by Staphylococci Isolated from Prosthetic Joint Infection
title 1586. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Biofilms Formed by Staphylococci Isolated from Prosthetic Joint Infection
title_full 1586. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Biofilms Formed by Staphylococci Isolated from Prosthetic Joint Infection
title_fullStr 1586. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Biofilms Formed by Staphylococci Isolated from Prosthetic Joint Infection
title_full_unstemmed 1586. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Biofilms Formed by Staphylococci Isolated from Prosthetic Joint Infection
title_short 1586. In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin Against Biofilms Formed by Staphylococci Isolated from Prosthetic Joint Infection
title_sort 1586. in vitro activity of rifampin, rifabutin, rifapentine, and rifaximin against biofilms formed by staphylococci isolated from prosthetic joint infection
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810379/
http://dx.doi.org/10.1093/ofid/ofz360.1450
work_keys_str_mv AT albanomariana 1586invitroactivityofrifampinrifabutinrifapentineandrifaximinagainstbiofilmsformedbystaphylococciisolatedfromprostheticjointinfection
AT karaumelissaj 1586invitroactivityofrifampinrifabutinrifapentineandrifaximinagainstbiofilmsformedbystaphylococciisolatedfromprostheticjointinfection
AT osmondouglasr 1586invitroactivityofrifampinrifabutinrifapentineandrifaximinagainstbiofilmsformedbystaphylococciisolatedfromprostheticjointinfection
AT oraveccaitlinp 1586invitroactivityofrifampinrifabutinrifapentineandrifaximinagainstbiofilmsformedbystaphylococciisolatedfromprostheticjointinfection
AT abdelmatthewp 1586invitroactivityofrifampinrifabutinrifapentineandrifaximinagainstbiofilmsformedbystaphylococciisolatedfromprostheticjointinfection
AT patelrobin 1586invitroactivityofrifampinrifabutinrifapentineandrifaximinagainstbiofilmsformedbystaphylococciisolatedfromprostheticjointinfection